<DOC>
	<DOCNO>NCT01034644</DOCNO>
	<brief_summary>This study , PRISMS-15 single visit , exploratory pharmacogenetic trial long-term follow-up PRISMS ( Prevention Relapses Disability Interferon beta-1a Subcutaneously Multiple Sclerosis ) trial . The aim trial provide additional data drive factor IFN beta response long-term outcome RebifÂ® treatment . This Phase IV trial involve subject previously participate PRISMS trial . To address trial objective , single visit perform , least 3 month onset last relapse .</brief_summary>
	<brief_title>Pharmacogenetic Trial Long-term Follow-up PRISMS Trial ( PRISMS-15 )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Was randomize PRISMS study Is willing able comply protocol Written inform consent give trialrelated activity carry Is unwilling unable participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Biomarkers</keyword>
	<keyword>Genetic marker</keyword>
</DOC>